Boehringer Ingelheim inaugurates the Shanghai "Center of Competence"

Boehringer IngelheimBoehringer Ingelheim celebrated the inauguration of its new "Center of Competence" (CoC) in Shanghai. As part of the company's EUR 100 million expansion project in China, the CoC entails an investment of EUR 10 million and will specialise in optimising active pharmaceutical ingredients (APIs) and chemical intermediates procured in China. So far, more than 20 highly-qualified organic and analytical chemists have been recruited for the CoC.

"This reinforces our company's determination and commitment to continue investing in China," said Prof. Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim and responsible for the Board Division Human Resources and Operations. "We attach great importance to the exchange with our Chinese partners. We have a long-term commitment to this market and we are driving innovation in the country's pharmaceutical industry."

The new CoC consists of the two departments Process Development (PD) and Quality Control (QC). The main functions of PD are to focus on the production process optimisation and the corresponding technology transfer to the company's partners within China in order to increase the production efficiency and precision.

David Preston, Chief Executive Officer of Boehringer Ingelheim China, said: "The inauguration of CoC is a milestone for Boehringer Ingelheim's development in China. By optimising the production process of our partners and securing the quality of the intermediates, China will play a stronger role in the company's global procurement efforts."

In 2009, the company announced a EUR 100 million expansion plan in China to expand its production capacity in Shanghai Zhangjiang High-Tech Park and to set up the center of competence which is now being opened.

About Boehringer Ingelheim in China
The laboratories of CoC are currently located at Waigaoqiao Free Trade Zone, Pudong, Shanghai. It covers an area of about 2,000 square meters. The CoC has been tested since May 2010 and is scheduled to be officially in operation in September 2010.

Boehringer Ingelheim set up its China branch office in March 1994. A year later, Boehringer Ingelheim International Trade (Shanghai) Co., Ltd. was registered. In 1995, Boehringer Ingelheim Shanghai Pharmaceuticals Ltd. was established. In 2002, the company set up its production plant in Shanghai Zhangjiang High-tech Park. It has introduced a state-of-the-art manufacturing facility that strictly follows international GMP standards. Currently, the company has offices in Shanghai, Beijing, Guangzhou and Chengdu with around 2,000 employees.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is recognised for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. In recent years, the company also successfully advanced its research in diseases including diabetes and tumors. In 2009, Boehringer Ingelheim posted net sales of EUR 12.7 billion while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...